IP Library Granted Patent US 9,050,296
Granted Patent B2
US 9,050,296 · App. 13/934,455 · Granted Jun 9, 2015

Methods for treating metabolic syndrome with Cthrc1 polypeptide

Inventor: Volkhard Lindner (South Portland, ME)
Assignee: MAINE MEDICAL CENTER
A61K38/1709G01N33/53A01K67/0276C07K14/47C07K16/18G01N33/6893C07K2317/34G01N2800/04G01N2800/50A61K48/005C07K14/78A01K2217/075A01K2227/105A01K2267/0362
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,050,296
App. No.
13/934,455
Granted
Jun 9, 2015
Kind
B2
Abstract

The present invention features compositions and methods for treating and preventing a metabolic syndrome featuring the collagen triple helix repeat containing-1 (Cthrc1) protein.

Claims (10)

1. A method of treating metabolic syndrome or a metabolic syndrome associated condition in a subject, the method comprising

administering an effective amount of a Collagen Triple Helix Repeat Containing 1 (Cthrc1) polypeptide to the subject, wherein said Cthrc1 polypeptide is at least 95% identical to SEQ ID NO: 1, thereby treating metabolic syndrome.

2. The method of claim 1 , wherein said metabolic syndrome associated condition is selected from the group consisting of type II diabetes, hyperlipidemia, elevated triglycerides, elevated blood pressure or hypertension, hyperglycemia, and obesity.

3. The method of claim 1 , wherein said method further comprises reducing excess lipid and increasing glycogen storage in a tissue or organ of a subject.

4. The method of claim 3 , wherein the effective amount of Cthrc1 is sufficient to reduce lipids in target organs by at least 40%.

5. The method of claim 1 , wherein said method further comprises treating steatosis in a subject.

6. The method of claim 5 , wherein the steatosis is selected from the group consisting of hepatic steatosis and cardiac steatosis.

7. The method of claim 1 , wherein the polypeptide is administered systemically.

8. The method of claim 1 , wherein the method reduces the risk of heart disease or diabetes.

9. The method of claim 1 , wherein the method comprises identifying the subject as having a metabolic syndrome or an associated condition.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 31, 2015
From: MAINE MEDICAL CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 037406/0751 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2013
From: LINDNER, VOLKHARD
To: MAINE MEDICAL CENTER
Reel/Frame 031136/0420 →
Continuity (2)
Provisional Application 61667713 · Jul 3, 2012
Related Publication 20140011737A1 · Jan 9, 2014